RxDoctor Payments Data

Claude Galphin

Nephrology · Chattanooga, TNNPI 1700883816

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,878 of the $3,711 with a category attached, or 77.6%. 12 manufacturers reported payments, led by Boehringer Ingelheim at 58.3% of the total. 2025 is the largest year on record at $2,165, 9.6 times the $226 reported in 2019.

$3,711in general payments, 2019–2025

Across 34 payments — averaging $109.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • CSL Behring$1K
  • AstraZeneca$96
  • Otsuka America Pharmaceutical, Inc.$91
  • Vifor Pharma, Inc.$42
  • Mallinckrodt Hospital Products Inc.$30
  • plus $106 from 6 others
$2,003,486in research payments, 2019–2025

Across 749 payments — averaging $2674.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Akebia Therapeutics Inc$1.1M
  • Vertex$226K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$190K
  • AstraZeneca$156K
  • Gilead$107K
  • CSL Behring$67K
  • plus $168K from 9 others

What the payments were for

  • Travel & lodging$2,87878%
  • Food & beverage$83322%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,711 in reported general payments places this provider in the 75th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee →

Other nephrology in Chattanooga

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →